Effect of ritonavir and saquinavir on Candida albicansgrowth rate and in vitroactivity of aspartyl proteinases

References

• Cassone A, De Bernardis F, Torosantucci A, et al. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 448–453.
   PubMed Web of Science ®Google Scholar
• Hood S, Bonington A, Evans J, et al. Reduction in orophar-yngeal candidiasis following introduction of protease inhibitors. AIDS 1998; 12: 447–448.
   PubMed Web of Science ®Google Scholar
• Diz P, Ocampo A, Iglesias I, et al. Lack of ritonavir antifungal effect in vitro. Antimicrob Agents Chemother 1999; 43: 997.
   Google Scholar
• Gottfredsson M, Cox GM, Indridason OS, et al. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999; 180: 534–537.
   Web of Science ®Google Scholar
• Klein RS, Arnsten JH, Sobel JD. Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infec-tion. J Infect Dis 2000; 181: 812.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Refer-ence method for broth dilution antifungal susceptibility testing of yeast; approved standard. vol. 17, no 9. Document M27-A. National Committee for Clinical Laboratory Standards, Villa-nova, Pa., 1997.
   Google Scholar
• Cassone A, De Bernardis F, Mondello F, et al. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987; 156: 777–783.
   PubMed Web of Science ®Google Scholar
• Ruche' R, Tegeler R, Trost M. A comparison of secretory proteinases from different strains of Candida albicans. Sabour-audia 1982; 20: 233–244.
   Google Scholar
• Bradford MM. A rapid and sensitive method for the quantifica-tion of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–254.
   PubMed Web of Science ®Google Scholar
• Blanco MT, Perez-Giraldo C, Blanco J, et al. In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method. Antimicrob Agents Chemother 1992; 36: 898–901.
   Google Scholar
• Hube B, Sanglard D, Odds FC, et al. Gene disruption of each of the secreted aspartyl proteinase genes 5AP1, 5AP2, and 5AP3 of Candida albicans attenuates virulence. Infect Immun 1997; 65: 3529–3538.
   PubMed Web of Science ®Google Scholar
• Cutler JE. Putative virulence factors of Candida albicans. Annu Rev Microbiol 1991; 45: 187–218.
   PubMed Web of Science ®Google Scholar
• Chaffin WL, LOpez-Ribot JL, Casanova M, et al. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol. Mol Biol Rev 1998; 62: 130–180.
   Google Scholar
• Borg-von Zepelin M, Meyer I, Thomssen R, et al. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 1999; 113: 747–751.
   Google Scholar
• Korting HC, Schaller M, Eder G, et al. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-Infected patients. Antimicrob Agents Chemother 1999; 43: 2038–2042.
   PubMed Web of Science ®Google Scholar
• Monod M, Borg-von Zepelin M, Telenti A, et al. The inhibition of Candida albicans secreted aspartic proteases by three different HIV protease inhibitors. Dermatology 1999; 198: 412–414.
   Google Scholar
• Gruber A, Speth C, Lukasser-Vogl E, et al. Human immuno-deficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999; 41: 227–234.
   Google Scholar
• Gottfredson M, Cox GM, Perfect JR. Reply to: Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181: 812–813.
   Google Scholar
• Diz Dios P, Ocampo A, Otero A, et al. Changes in orophar-yngeal colonization and infection by Candida albicans in human immunodeficiency virus-infected patients. J Infect Dis 2001; 183: 355–356.
   Google Scholar